Long stress-induced non-coding transcript 5 (LSINCT5)

Long stress-induced non-coding transcript 5 (LSINCT5) is a long non-coding RNA (lncRNA) of approximately 2.6 kb, transcribed intergenically in human chromosome 5p, possibly by RNA polymerase III. LSINCT5 is upregulated in several human cancers, including non-small cell lung cancer, endometrial carcinoma, breast cancer, and others. In cancer cells, LSINCT5 promotes cell proliferation, migration, invasion, and metastasis. Mechanistically, LSINCT5 interacts with proteins such as HMGA2, stabilizing them through inhibition of proteasomal degradation, and acts as a competing endogenous RNA ("molecular sponge") for microRNAs such as miR-30a, thereby modulating signaling pathways like Wnt/β-catenin. Increased LSINCT5 expression correlates with advanced pathological stage and poor prognosis, supporting its potential as an oncogenic biomarker and putative therapeutic target in oncology. Direct or indirect inhibitors of LSINCT5 may offer novel avenues for cancer intervention, although no clinically approved drugs specifically target this RNA at present.

Other names

LSINCT5

No approved drugs target LSINCT5 directly, but the proposed mechanism includes: - siRNA/shRNA knockdown of LSINCT5 reduces cancer cell proliferation and migration - LSINCT5 acts as a molecular sponge for certain microRNAs (e.g., miR-30a), modulating downstream signaling pathways (e.g., Wnt/β-catenin pathway) - Pharmacological intervention at the LSINCT5/HMGA2 axis is proposed as a potential future approach